OakChart

Immunome Inc

IMNMHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 9:46 AM ET

18.93+0.28 (1.53%)
2026-11-11 15:46 CET
Market cap
2,200.76 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-282.65 USD m
Free cash flow, TTM
-238.70 USD m
EPS diluted, TTM
-2.63
P/E
-
Compare

Price

IMNM against its 20, 50 and 200-day averages
2050200beatmiss
20.0025.0030.002.2M4.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IMNMclose 18.9420-day 18.3950-day 20.99200-day 22.2718.94

37.0% under 30.06 on 19 Aug 2026. Last 15 sessions, 31.7% high to low

Profile

IMNM
52-week range, 20% of the way up
16.1130.06

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

IndexRUT
Employees177
IPOOct 02, 2020
Beta2.66
ATR, 14d1.29
Rel volume0.52
Short float14.95%
Insider own8.30%
Inst own100.27%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.24B
Enterprise Value1.79B
Income-282.65M
Sales0.00M
Book/sh4.00
Cash/sh3.91
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees177
IPOOct 02, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.74
P/C4.84
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio11.66
Current Ratio11.66
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.63
EPS next Y-2.64
EPS next Q-0.72
EPS this Y-2.27%
EPS next Y-6.18%
EPS next 5Y12.08%
EPS past 3/5Y7.72% -7.71%
Sales past 3/5Y- -
EPS Y/Y TTM11.09%
Sales Y/Y TTM-100.00%
EPS Q/Q-15.65%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.-3.43% -100.00%

Ownership

Insider Own8.30%
Insider Trans-6.59%
Inst Own100.27%
Inst Trans-0.67%
ROA-70.23%
ROE-78.71%
ROIC-60.84%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA202.99%
SMA50-9.78%
SMA200-14.99%
Trades-

Technical

Shs Outstand113.65M
Shs Float108.21M
Short Float14.95%
Short Ratio11.83
Short Interest16.17M
52W High30.06 -37.01%
52W Low16.11 17.54%
Volatility11.58% 6.95%
ATR (14)1.29
RSI (14)47.72
Beta2.66
Rel Volume0.52
Avg Volume1.37M
Volume63,540

Performance

Perf Week-3.00%
Perf Month7.71%
Perf Quarter-28.33%
Perf Half Y-14.71%
Perf YTD-11.85%
Perf Year8.08%
Perf 3Y134.05%
Perf 5Y3.70%
Perf 10Y-
Recom1.18
Target Price35.13
Prev Close18.65
Price18.93
Change %1.53%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedWWilliam BlairOutperform
Oct 01, 2026InitiatedSStifelHold$24+26.7%
Sep 21, 2026InitiatedAAlliance Global PartnersBuy$32+69.0%
May 28, 2026InitiatedBBarclaysOverweight$36+90.1%
Feb 12, 2026InitiatedHH.C. WainwrightBuy$40+111.2%
Dec 01, 2025InitiatedTTruistBuy$36+90.1%
Sep 22, 2025InitiatedGGoldmanBuy$26+37.3%
Sep 05, 2025InitiatedCCraig HallumBuy$26+37.3%
Apr 02, 2025InitiatedLLake StreetBuy$23+21.5%
Nov 08, 2024InitiatedSStephensOverweight$30+58.4%

Peers

Mkt cap
TickerCompanyMkt cap
ZYMEZymeworks BC Inc2.14B
CTMXCytomX Therapeutics Inc431.30M
STROSutro Biopharma Inc168.30M
IDYAIdeaya Biosciences Inc3.06B
PYXSPyxis Oncology Inc194.06M
TNGXTango Therapeutics Inc4.09B
AKTSAktis Oncology Inc964.95M
BCYCBicycle Therapeutics Plc ADR187.07M
ADCTAdc Therapeutics SA186.40M
CATXPerspective Therapeutics Inc97.11M

Insider trading

latest 14 of 52
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Higgins JackChief Scientific OfficerSep 11 '26Option Exercise1.3518,00024,30078,250Sep 15 04:30 PM
Higgins JackChief Scientific OfficerSep 11 '26Sale25.3213,200334,22465,050Sep 15 04:30 PM
Higgins JackOfficerSep 11 '26Proposed Sale25.3213,200334,224Sep 11 10:20 AM
Barchas IsaacDirectorAug 11 '26Sale26.2362,2911,633,8930Aug 12 05:47 PM
Barchas IsaacDirectorAug 12 '26Sale27.2511,048301,05892,211Aug 12 05:47 PM
Barchas IsaacDirectorAug 10 '26Sale26.0710,125263,95962,291Aug 12 05:47 PM
Barchas IsaacDirectorAug 12 '26Proposed Sale27.2511,048301,058Aug 12 11:40 AM
Barchas IsaacDirectorAug 06 '26Sale26.0620,840543,09087,664Aug 10 04:10 PM
Barchas IsaacDirectorAug 07 '26Sale26.0615,248397,36372,416Aug 10 04:10 PM
Horn KinneyCHIEF BUSINESS OFFICERAug 04 '26Option Exercise11.8990,6161,077,37990,616Aug 06 06:30 PM
Horn KinneyCHIEF BUSINESS OFFICERAug 04 '26Sale25.0990,6162,273,5550Aug 06 06:30 PM
ABHMC II, LLCShareholderAug 06 '26Proposed Sale25.52108,5042,769,022Aug 06 05:41 PM
Horn KinneyOfficerAug 04 '26Proposed Sale25.0990,6162,274,007Aug 04 04:32 PM
Horn KinneyCHIEF BUSINESS OFFICERJul 07 '26Option Exercise12.921,09214,1091,092Jul 09 05:38 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
CANCTema Oncology ETFAUM: 217.09M
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B

News

latest 14 of 206
  • Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update (Business Wire)
  • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026 (Business Wire)
  • Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference (Business Wire) +7.58%
  • Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors (Business Wire)
  • Loading…
  • Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 (Business Wire)
  • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.79%
  • Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors (Business Wire)
  • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
  • Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire) +6.63%
  • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.643-0.622-0.7600.000.1515
2026Q22026-08-11-0.650-0.514-0.6460.000.1714
2026Q12026-05-12-0.480-0.556-0.4760.000.2213
2025Q42026-03-03-0.760-0.590-0.7520.000.8814
2025Q32025-11-06-0.650-0.566-0.6530.000.8012
2025Q22025-08-06-0.500-0.517-0.4994.020.839
2025Q12025-05-12-0.520-0.635-0.5242.930.789
2024Q42025-03-19-1.110-0.641-1.2802.743.158
2024Q32024-11-13-0.780-0.551-0.7822.912.297
2024Q22024-08-12-0.600-0.379-0.6032.361.876
2024Q12024-05-14-2.510-0.680-2.5121.032.805
2023Q42024-03-28-4.210-0.273-4.2203.842.073
2023Q32023-11-09-0.360-0.170-0.3563.57-1
2023Q22023-08-09-0.460-0.160-0.4564.260.001
2023Q12023-05-05-0.3500.585-0.3512.360.002
2022Q42023-03-16-0.640-0.675-0.6930.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-5.260-8.630-1.6770.002.10
2021FY-2.140-2.320-2.1420.000.00
2022FY-3.090-3.075-3.0940.000.00
2023FY-5.380-0.920-5.38214.0212.27
2024FY-5.000-4.382-4.9969.049.41
2025FY-2.430-2.244-2.4426.947.72
2026FY--2.477--0.15
2027FY--2.640--46.62
2028FY--1.643--171.5
2029FY--0.616--318.67
2030FY-0.852--571.63

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1013000.150.002.00
2026Q4S2026-11-0913000.150.002.00
2026Q4S2026-10-1413000.150.002.00
2026Q4S2026-09-2912000.170.002.00
2026Q4S2026-08-2111000.180.002.00
2026Q4S2026-08-1212000.170.002.00
2026Q4S2026-07-2711000.180.002.00
2026Q4S2026-07-2311010.180.002.00
2026Q4S2026-05-2712012.380.0026.60
2026Q4S2026-05-1311012.600.0026.60
2026Q4S2026-03-299015.740.0026.60
2026Q4S2026-03-0410015.170.0026.60
2026Q4S2026-02-258009.340.0046.10
2026Q4S2026-02-118119.340.0046.10

Estimate history

EPS, annual-0.746-0.993-1.677-2.142-3.094-5.382-4.996-2.432-2.6285
Period20182019202020212022202320242025TTM
EPS, quarterly-0.782-1.28-0.524-0.499-0.653-0.752-0.476-0.646-0.755
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000014.0189.0416.9410
Period20182019202020212022202320242025TTM
Sales, quarterly2.912.7382.9264.01500000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual10.5210.5210.63412.1112.12943.25264.461113.133113.647
Period20182019202020212022202320242025MRQ
Shares, quarterly60.42264.46186.95687.01391.707113.133113.171113.399113.647
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.006.949.0414.020.000.000.000.000.00
Cost of Goods Sold Incl. D&A3.752.962.100.730.630.760.760.610.52
Gross Profit-3.753.996.9413.29-0.63-0.76-0.76-0.61-0.52
Selling, General and Administrative Excl. Other286.93218.10160.40122.8236.2724.4511.519.737.22
Research and Development226.54174.33127.44103.1622.6413.366.738.216.36
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-290.69-214.11-153.46-109.53-36.90-25.20-12.26-10.35-7.74
Interest Expense0.000.000.000.00-0.010.040.110.14
Unusual Expense-10.00152.340.000.00-0.505.540.000.00
Net Income Before Taxes-282.65-212.39-292.96-106.81-36.90-24.71-17.84-10.44-7.84
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-282.65-212.39-292.96-106.81-36.90-24.71-17.84-10.44-7.84
Net Income From Continuing Operations-282.65-212.39-292.96-106.81-36.90-24.71-17.84-10.44-7.84
Net Income-282.65-212.39-292.96-106.81-37.52-24.71-17.84-10.44-7.84
EPS (Recurring)-2.49-2.35-3.18-5.38-3.09-2.17-1.31-0.99-0.75
EPS (Basic, Before Extraordinaries)-2.63-2.43-5.00-5.38-3.09-2.14-1.68-0.99-0.75
EPS (Diluted)-2.63-2.43-5.00-5.38-3.09-2.14-1.68-0.99-0.75
EBITDA-286.93-211.16-151.35-108.80-36.27-24.45-11.51-9.73-7.22
Non-Operating Income (Expense)18.0411.7212.842.720.010.000.000.010.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense37.4125.6915.756.225.333.450.620.010.01
Price To Sales Ratio-270.3268.8815.15-----
Gross Margin-57.4376.7594.81-----
Operating Margin--3,084.76-1,697.33-781.35-----
Net Margin--3,059.99-3,240.38-761.92-----
Shares Outstanding113.65113.1364.4643.2512.1312.1110.6310.5210.52
Market Capitalization2,200.762,200.76662.87457.2126.80156.82102.04100.78-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.004.012.932.74
Cost of Goods Sold Incl. D&A1.061.160.750.780.730.720.730.59
Gross Profit-1.06-1.16-0.75-0.78-0.733.292.202.14
Selling, General and Administrative Excl. Other89.3076.9758.5862.0959.4149.7746.8457.74
Research and Development69.5159.8846.3850.7749.1940.4536.8747.30
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-90.36-78.14-59.33-62.86-60.14-46.48-44.64-55.60
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.00-10.000.000.000.0027.37
Net Income Before Taxes-85.78-73.13-53.84-69.90-57.46-43.40-41.64-80.25
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-85.78-73.13-53.84-69.90-57.46-43.40-41.64-80.25
Net Income From Continuing Operations-85.78-73.13-53.84-69.90-57.46-43.40-41.64-80.25
Net Income-85.78-73.13-53.84-69.90-57.46-43.40-41.64-80.25
EPS (Recurring)-0.76-0.65-0.48-0.68-0.65-0.50-0.52-0.97
EPS (Basic, Before Extraordinaries)-0.76-0.65-0.48-0.75-0.65-0.50-0.52-1.28
EPS (Diluted)-0.76-0.65-0.48-0.75-0.65-0.50-0.52-1.28
EBITDA-89.30-76.97-58.58-62.09-59.41-45.76-43.91-55.00
Non-Operating Income (Expense)4.585.015.492.962.683.083.002.72
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.768.807.957.896.755.355.705.47
Price To Sales Ratio--616.26287.80106.4164.2848.8673.66
Gross Margin-----82.0775.1978.27
Operating Margin------1,157.61-1,525.50-2,030.61
Net Margin------1,080.87-1,423.10-2,930.93
Shares Outstanding113.65113.40113.17113.1391.7187.0186.9664.46
Market Capitalization2,200.762,399.772,474.222,370.001,019.30809.21585.18662.87

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments653.48217.30138.1420.3249.2339.772.541.60
Short Term Receivables0.000.000.290.854.310.900.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets7.294.046.271.483.102.230.580.51
Total Current Assets660.78221.34144.7022.6556.6442.893.122.11
Net Property, Plant & Equipment17.6114.393.640.960.851.531.702.08
Total Investments and Advances0.210.100.100.100.100.100.100.10
Intangible Assets---0.000.000.00--
Other Assets4.594.410.100.330.330.000.140.15
Total Assets683.19240.24148.5424.0557.9244.525.064.45
Short Term Debt Incl. Current Port. of LT Debt0.000.060.310.060.000.480.450.61
Accounts Payable3.3414.193.312.403.081.190.550.47
Other Current Liabilities41.6540.0518.214.876.651.370.670.48
Total Current Liabilities44.9954.3121.837.339.733.041.671.56
Long Term Debt3.854.771.340.000.000.1339.0128.08
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.005.490.060.010.010.020.01
Total Liabilities48.8459.0828.667.399.743.1840.6929.65
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity634.34181.16119.8816.6548.1941.34-35.63-25.20
Total Shareholders Equity634.34181.16119.8816.6548.1941.34-35.63-25.20
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity634.34181.16119.8816.6548.1941.34-35.63-25.20
Total Liabilities & Stockholders Equity683.19240.24148.5424.0557.9244.525.064.45
Book Value Per Share5.612.812.771.373.983.89-3.39-2.40
Tangible Book Value Per Share5.612.812.771.373.983.89-3.39-2.40
Full-Time Employees1771185537392321-
Price to Book Ratio4.672.9921.491.163.262.49-2.05-
Return on Assets-46.00-150.71-123.77-90.02-48.24-71.95-219.69-
Return on Equity-52.09-194.63-156.45-113.81-55.20-624.22--
Return on Invested Capital-33.28-157.56-88.11-221.56-51.28-43.00-309.27-273.15
Quick Ratio14.694.086.633.095.8214.121.881.35
Current Ratio14.694.086.633.095.8214.121.881.35

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-282.65-212.39-292.96-106.81-36.90-24.71-17.84-10.44-7.84
Depreciation3.752.962.100.730.630.760.760.610.52
Other Funds (Non Cash)46.5133.75165.1986.515.332.956.160.020.02
Funds from Operations-232.38-175.69-125.67-19.57-30.93-21.00-10.93-9.81-7.30
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.35-15.2314.8712.002.242.78-1.210.21-0.10
Cash from Operating Activities-229.03-190.92-110.79-7.57-28.69-18.23-12.13-9.60-7.41
Capital Expenditures-9.67-9.69-7.17-0.83-0.25-0.08-0.59-0.23-0.23
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-248.1876.73-31.55-38.930.000.000.000.000.00
Purchase of Investments-302.18-123.27-186.56-38.930.000.000.000.000.00
Sale Or Maturity of Investments54.00200.00155.000.000.000.000.000.000.00
Other Uses-9.01-6.25-46.340.000.000.000.000.000.00
Other Sources0.000.000.009.280.000.000.000.000.00
Cash from Investing Activities-266.8660.80-85.06-30.48-0.25-0.08-0.59-0.23-0.23
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock436.09640.36240.53-8.590.0327.8849.894.590.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00-0.05-0.040.00
Sale of Common Pref Stock436.09640.36240.53-8.590.0327.8849.944.620.00
Proceedsfrom Stock Options432.36639.44238.50-8.960.0026.4449.924.620.00
Issuance or Reduction of Debt, Net0.000.000.000.000.00-0.110.056.19-0.55
Change in Long Term Debt0.000.000.000.000.00-0.110.056.19-0.55
Issuance of Long Term Debt0.000.000.000.000.000.000.506.800.00
Reduction of Long Term Debt0.000.000.000.000.00-0.11-0.45-0.61-0.55
Net Financing Active Other Cash Flow0.000.000.00125.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities436.09640.36240.53116.410.0327.7749.9410.77-0.55
Net Change in Cash-59.80510.2444.6778.36-28.919.4637.220.94-8.19
Free Cash Flow-238.70-200.60-117.97-8.40-28.94-18.30-12.72-9.83-7.63
Preferred Dividends (Cash Flow)-0.000.000.00-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments461.58522.70582.69653.48272.64268.04
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets16.2115.7511.627.297.299.40
Total Current Assets477.80538.45594.31660.78279.92277.43
Net Property, Plant & Equipment20.5521.3019.9117.6114.6914.29
Total Investments and Advances0.210.210.210.210.210.21
Other Assets6.975.425.364.594.554.35
Total Assets505.53565.38619.79683.19299.38296.29
Short Term Debt Incl. Current Port. of LT Debt1.130.150.000.000.000.00
Accounts Payable4.466.005.533.346.154.66
Other Current Liabilities35.3829.5721.8841.6525.3018.22
Total Current Liabilities40.9735.7127.4144.9931.4522.88
Long Term Debt10.264.593.693.854.014.14
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities51.2240.3031.1148.8435.4627.02
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity454.30525.08588.69634.34263.92269.27
Total Shareholders Equity454.30525.08588.69634.34263.92269.27
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity454.30525.08588.69634.34263.92269.27
Total Liabilities & Stockholders Equity505.53565.38619.79683.19299.38296.29
Book Value Per Share4.004.635.205.612.883.09
Tangible Book Value Per Share4.004.635.205.612.883.09
Full-Time Employees---177-155
Price to Book Ratio4.674.073.907.463.782.63
Return on Assets-70.23-59.03-46.67-46.00-80.08-71.69
Return on Equity-78.71-64.03-50.14-52.09-93.04-81.20
Return on Invested Capital-18.47-13.81-9.09-10.95-21.44-15.87
Quick Ratio11.6615.0821.6814.698.9012.13
Current Ratio11.6615.0821.6814.698.9012.13

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-85.78-73.13-53.84-69.90-57.46-43.40
Depreciation1.061.160.750.780.730.72
Other Funds (Non Cash)12.188.358.0317.955.885.03
Funds from Operations-72.54-63.61-45.05-51.18-50.84-37.64
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital11.791.92-13.583.2210.33-11.76
Cash from Operating Activities-60.75-61.69-58.64-47.95-40.51-49.40
Capital Expenditures-0.49-2.18-3.00-4.00-1.12-0.91
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments54.00-302.180.000.00125.00-63.27
Purchase of Investments0.00-302.180.000.000.00-123.27
Sale Or Maturity of Investments54.000.000.000.00125.0060.00
Other Uses0.000.00-9.010.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities53.51-304.35-12.02-4.00123.88-64.17
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.381.06-0.14432.8045.39-0.06
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.381.06-0.14432.8045.39-0.06
Proceedsfrom Stock Options0.000.00-0.36432.7244.98-0.27
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.381.06-0.14432.8045.39-0.06
Net Change in Cash-4.86-364.99-70.79380.84128.76-113.63
Free Cash Flow-61.24-63.87-61.64-51.95-41.63-50.31

Revenue breakdown

Pharmaceutical Preparations2024: 9.04M 2025: 6.94M
United States2024: 9.04M 2025: 6.94M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.95%16.2M108.2M1.28M
2026-10-1515.97%17.3M108.2M1.20M
2026-09-3015.66%16.8M107.0M1.23M
2026-09-1515.77%16.2M103.0M1.29M
2026-08-3115.18%15.6M103.0M1.39M
2026-08-1416.89%17.4M103.0M1.39M
2026-07-3117.53%18.0M102.6M1.33M
2026-07-1516.74%17.2M103.0M1.35M
2026-06-3016.88%17.4M102.9M1.31M
2026-06-1517.68%18.1M102.7M1.23M
2026-05-2916.42%16.9M102.7M1.19M
2026-05-1517.17%17.6M102.7M1.14M
2026-04-3018.17%18.7M102.7M1.21M
2026-04-1518.12%18.6M102.7M1.37M
2026-03-3118.51%18.9M102.3M1.59M
2026-03-1317.48%17.9M102.3M2.07M
2026-02-2717.48%17.9M102.3M2.03M
2026-02-1316.08%16.0M99.8M2.10M
2026-01-3015.58%15.8M101.2M2.14M
2026-01-1515.13%15.3M101.2M2.02M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call10.000.000.000.00-0.000.00---
call11.000.000.000.00-0.000.00---
call12.000.000.000.00-0.000.00---
call13.000.000.000.00-0.000.00---
call14.000.000.000.00-0.000.00---
call15.000.000.000.00-0.000.00---
call16.000.000.000.00-0.000.00---
call17.000.000.000.60-3790.00---
call18.000.000.001.95-35.000.00---
call19.000.000.001.35-60.000.00---
call20.000.000.002.00-1060.00---
call21.000.000.000.63-46.000.00---
call22.000.000.000.40-5.000.00---
call23.000.000.000.54-7.000.00---
call24.000.000.001.55-1.000.00---
call25.000.000.000.20-6.000.00---
call26.000.000.001.10-2.000.00---
call27.000.000.001.75-4.000.00---
call28.000.000.002.05-5.000.00---
call29.000.000.001.30-3.000.00---
call30.000.000.000.45-5.000.00---
call31.000.000.001.00-2.000.00---
call32.000.000.000.80-3.000.00---
call35.000.000.000.00-0.000.00---
put10.000.000.000.00-0.000.00---
put11.000.000.000.00-0.000.00---
put12.000.000.000.00-0.000.00---
put13.000.000.000.10-14.000.00---
put14.000.000.000.15-1640.00---
put15.000.000.000.15-1060.00---
put16.000.000.000.40-2490.00---
put17.000.000.000.85-1400.00---
put18.000.000.003.50-5.000.00---
put19.000.000.001.25-91.000.00---
put20.000.000.002.65-50.000.00---
put21.000.000.003.00-20.000.00---
put22.000.000.004.24-1230.00---
put23.000.000.005.30-6.000.00---
put24.000.000.002.00-9.000.00---
put25.000.000.000.00-0.000.00---
put26.000.000.000.00-0.000.00---
put27.000.000.007.88-0.000.00---
put28.000.000.000.00-0.000.00---
put29.000.000.000.00-0.000.00---
put30.000.000.000.00-0.000.00---
put31.000.000.000.00-0.000.00---
put32.000.000.000.00-0.000.00---
put35.000.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-11-09S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-30SCHEDULE 13GSEC
2026-10-058-KCurrent report2026-10-02SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-06144Filing for proposed sale of securities under Rule 144.SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-07144Filing for proposed sale of securities under Rule 144.SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900334.22K1
2026-08005.41M6
2026-07005.94M5
2026-06204.26K14.52M4
2026-05103.50K100
2026-04001.63M2
2026-03544.27K31.34M2
2026-020000
2026-010000
2025-121.45M48.33M1
2025-110000

Institutional holders

Manager% owned
T. Rowe Price Investment Management, Inc.17.37%
FMR LLC15.00%
BlackRock, Inc.7.78%
STATE STREET CORP4.85%
WELLINGTON MANAGEMENT GROUP LLP4.60%
Redmile Group, LLC4.34%
PRIMECAP MANAGEMENT CO/CA/4.05%
VANGUARD CAPITAL MANAGEMENT LLC4.02%
DRIEHAUS CAPITAL MANAGEMENT LLC3.84%
Enavate Sciences GP, LLC3.19%

Funds

Fund% owned
T. Rowe Price Small-Cap Stock Fund, Inc.6.34%
Fidelity Growth Company Fund4.32%
T. Rowe Price Institutional Small-Cap Stock Fund3.45%
VANGUARD HEALTH CARE FUND3.27%
PRIMECAP Odyssey Aggressive Growth Fund3.26%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.85%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.64%
iShares Russell 2000 ETF2.42%
Select Biotechnology Portfolio1.88%
T. Rowe Price Small-Cap Value Fund, Inc.1.44%

OakChart. IMNM. Cached 15 minutes.